Loading company…
Nimble Therapeutics develops oral therapies for immune-mediated diseases using its drug discovery platform.
Founded in 2019 and based in Wisconsin, Nimble Therapeutics uses a proprietary discovery platform to develop oral therapies for immune-mediated diseases. The company focuses on identifying and optimizing drug candidates in immunology. In December 2024, AbbVie agreed to acquire Nimble from Roche Venture Fund and Telegraph Hill Partners for USD 200 million in cash.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in